

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)



(10) International Publication Number
WO 2023/102239 A1

(51) International Patent Classification:

A61P 31/18 (2006.01) C07F 9/00 (2006.01)
C07D 401/14 (2006.01) A61K 31/4439 (2006.01)

(21) International Application Number:

PCT/US2022/051734

(22) International Filing Date:

02 December 2022 (02.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/285,730 03 December 2021 (03.12.2021) US
63/356,889 29 June 2022 (29.06.2022) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: FARAND, Julie; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
GRAUPE, Michael; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US). GUNEY,
Tezcan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Fos-
ter City, California 94404 (US). KATO, Darryl; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, Califor-
nia 94404 (US). LI, Jiayao; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). LINK,
John O.; 74 Prospect Avenue, San Francisco, California
94110 (US). MACK, James B.C.; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US). MUN, Dong Min; 37312 Suncrest Street, Newark,
California 94560 (US). SAITO, Roland D.; 2201 Bridge-
pointe Parkway, Apt. 335, San Mateo, California 94404
(US). WATKINS, William J.; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
ZHANG, Jennifer R.; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US).

(74) Agent: CHOI, Lydia B. et al.; Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION

(57) Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said com-
pounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions pro-
vided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

WO 2023/102239 A1